|
|
|
|
|
|
Home | Recommend | Scoreboard | Previous Picks | Books | Search | Contact Us |
|
Stockprowler looks under the rocks to find those little stocks with
the potential to make the BIG moves. Stockprowler screens NASDAQ,
NYSE, AMEX, and OTC stocks trading under $1. These stocks offer the
speculator considerable leverage. It is not uncommon for these stocks
to make moves of 30%, 50%, or more. Please read our disclaimer before
trading in any stocks mentioned on this Website ... Here's the Stockprowler
Report for May 2007: |
|
||||||||||
|
Stockprowler picks 4 speculations for May 2007 Recent Stockprowler picks have made considerable gains since our last reporting. IAO (AMEX) closed at 57 cents on Friday May 4, 2007 up 307% since we picked it on January 7. DIMEZ is up 100% since our last report. We believe IAO and DIMEZ still have considerable upside potential in the near future. Also, CSYS going nowhere since our report has the potential to be the sleeper stock of the year… in our opinion.
Pharm Control Ltd. (OTC: PMCL) Pharm Control Ltd. is focused on the development of natural, no side effect supplements to cure diseases such as diabetes, high blood pressure and high cholesterol related sicknesses, digestive disorders, liver and kidney diseases. The first product in the development pipeline is Control 24 ®, a natural product that is focused on the diabetes and pre-diabetes market. Diabetes is the third leading cause of death in the U.S. after heart disease and cancer. It is a disease in which the body does not produce or properly use insulin necessary for the body to metabolize glucose (sugar). The glucose stays in your blood instead and its level then gets too high, causing you to have diabetes. Diabetes affects an estimated 20 million people in the United States with another 15 million not yet diagnosed with an economic cost of over $100 billion yearly. Globally, the costs are staggering. Western medicine prescribes lifestyle changes, medications, and daily blood tests for life since there is no cure, only treatments to control it and delay its devastating affects. Over time, complications from diabetes can lead to blindness, kidney failure, heart disease, nerve damage, and limb amputations. Current medications can have serious side-effects including anxiety or nervousness, confusion, difficulty concentrating; blurred vision; breathing problems such as rapid, deep breathing or difficulty breathing with activity; cold sweats, increased sweating; cool, pale skin; dark yellow or brown urine, or yellowing of the eyes or skin; diarrhea; drowsiness; muscle pain; nausea, vomiting; rapid gain in weight; skin rash or hives; slow heartbeat; tremors or shakiness; unusual tiredness or weakness; swelling of the hands, legs, and/or feet. Pharm Control Ltd. believes blood sugar can be maintained at healthy levels by pure Oriental medicine. Control 24 ® cleans the impure thick blood and as the result the liver become more efficient and the cholesterol level goes down as the result. According to the company, western medicine stimulates the pancreas resulting in the damage to the organ. It can completely destroy the pancreatic function and the patients have to rely on insulin. On the other hand Oriental diabetic medicine Control 24 ® aims at curing the cause of diabetes. Control 24 ® when taken in gradually decreasing amount makes the normal daily life possible. Diabetes, whether it is in early or chronic stage, manifests itself with fever. According to the Oriental medicine the general causes of diabetes are lung fever, stomach fever and kidney fever. They are believed to be affected by liver fever. This fever goes into blood stream and make blood impure and thick. For this reason, Oriental medicines for diabetes always contain compounds which clean the blood. The popular ingredients for that purpose are such as Rehmannia root, lotus root, mouse eye bean (Rhynchosia phaseoloides), red ginseng and garlic extract. Wasp's Nest (Nidus vespa), Jerusalem artichoke (Helianthus tuberosus), ten-thousand-year mushroom (Ganoderam lucidum), Korean Mulberry (Morus australis) are some other components of the Oriental diabetic medicines. These gradually restore the pancreatic function without complication, stabilize blood sugar level and clean the blood. Control 24 ® can achieve not only normalization of blood sugar but also cure the ailment through systemic management of diet, exercise and life-style. By curing the ailment it is possible to have normal life without life-long dependency on drugs. Control 24 ® is clinically proven to have no side effects and is guaranteed to be 100% effective. The key to Control 24 ® effectiveness lies in its secret blend of botanical ingredients combined from over ten years of laboratory trials and immuno-pharmacological research. Every ingredient plays its particular role and the botanical blend as a whole represents a powerful tool to normalize your blood sugar levels. Control 24 ® is a breakthrough in scientific research and works at the cellular level in stages as follows: 1. Reduces blood sugar levels: Control 24 ® interferes with glucose absorption from the intestine and prevents adrenal hormones from stimulating the liver to produce glucose, both of which directly reduce blood sugar levels. 2. Eliminates insulin resistance: Control 24 ® repairs cell receptors to better recognize insulin which virtually eliminates insulin resistance. Most medical sources agree that insulin resistance is the root cause of Type 2 diabetes. Cells are now much more successful at metabolizing glucose which further normalizes blood sugar levels. 3. Promotes insulin production: Control 24 ® stimulates the increased production of an organic compound that is naturally produced by the body. If you are Type 2, it is quickly converted to insulin by the pancreas for increased insulin output. If you are Type 1, this conversion is not possible due to destroyed beta cells. Instead, this organic compound remains and functions just like insulin as a natural alternative. With increased production over time, stress on the pancreas is relieved which allows it to naturally heal and develop new beta cells with a different signature. These new beta cells are not susceptible to the body's immune system malfunction. Pharm Control recently announced it has made an application and has had preliminary talks with Wal-Mart to become a new supplier. http://biz.yahoo.com/iw/070124/0206988.html PMCL traded 10 million shares on above average volume Friday May 4, 2007. PMCL closed at 1.6 cents. Approximately 66 million shares outstanding with insiders owning almost half. If a definitive agreement is signed with Wal-Mart to sell its natural healing products watch for shares of PMCL to move north… fast! Pharm Control Ltd. website: http://www.control24.114toronto.com/html/control24.php
IA Global, Inc. (AMEX: IAO) IAGlobal Inc. is a Tampa-based public holding company focused on acquiring primarily Asian Pacific companies that operate in the telecommunication and finance markets. It owns Global Hotline Inc., which operates call centers and is a reseller of telephone and broadband lines and medical insurance in Japan. It also owns 36 percent of Australian Secured Financial Limited which raises funds through the issuance of debentures in Australia and provides short term loans for business or investment in Australia secured by real property. The Tampa-based company reported a net loss of $1.5 million for the 3rd quarter 2006, or 1 cent a share, on revenue of $4.5 million. The loss resulted from five contracts closed by Global Hotline during 2006 when it shifted its telecommunications business to higher margin contracts during September. The company projects the strategy change to increase revenue and profits starting in the fourth quarter of 2006. IA Global recently closed its equity investment in Australian Secured Financial Limited and its affiliates. The transaction added $7 million to IA Global's shareholders' equity. Global Hotline now operates four call centers, employs 462 full and part-time personnel. IAO closed at $0.14 on Friday January 5. A recent check has outstanding shares at 109 million, with 15 million shares in the float and 73% of the outstanding shares held by insiders.
Dime Bancorp Litigation Tracking Warrants (NasdaqNM:DIMEZ) Stockprowler first looked at DIMEZ back in April 2005 when the Anchor Savings Bank vs United States case was being litigated in Federal Court. It looked like it had 10 bagger plus potential back then and we believe it still does. So what is this all about? The lawsuit was filed against the United States government way back in January of 1995 by Anchor Bancorp, which later merged with Dime Bancorp. Between 1982 and 1985, Anchor acquired 8 failing savings and loan operations. Four of the acquisitions involved financial assistance from the Federal Savings and Loan Insurance Corporation (FSLIC). Liabilities in these transactions exceeded assets by $650 million. Anchor alleged that FSLIC agreed that this sum could be recorded as goodwill, and that Anchor would not have made the acquisitions if this had not been the case. Enacted in 1989, the Financial Institutions Reform, Recovery, and Enforcement Act required that the aforementioned goodwill be eliminated immediately. The company argues that this action placed severe restrictions on its activities and forced the company to sell valuable assets under liquidation-like circumstances. Washington Mutual (NYSE: WM) bought out Dime Bancorp several years ago and inherited Dime Bancorp's lawsuit. The DIMEZ financial instruments are termed warrants, but in fact, are more akin to rights. They offer the buyer an opportunity to receive common stock if a particular event not related to price of the common stock occurs. There is no exercise price, nor is there a definitive expiration date... the warrants expire shortly after litigation has been concluded. The warrants offer purchasers the opportunity to receive 85% of a settlement after taxes and lawyers fees have been taken out. The warrants trade as DIMEZ, although the underlying stock for the warrants is Washington Mutual (NYSE:WM). The number of shares of Washington Mutual that a holder of the DIMEZ warrants is entitled to after settlement of the litigation is difficult to determine and is dependent on several variables. The trial itself was concluded in July 2005 and we are awaiting the court's decision. The court could award anything from $0 to $983 million. If the judge were to award the maximum amount, it would make the DIMEZ warrants worth somewhere between $7 and $8 …or over 40 times the 17 cents that they closed at on Friday! Far fetched you say? Well, in another S&L breach of contract lawsuit filed against the U.S. government, that of Glendale Federal Bank, Chief Judge Loren A. Smith found that the government was liable for $908.9 million in damages! Of course, you could also receive nothing. In the event that the court does not award damages, the warrants would be worthless. It is a crap shoot. Don't wager more than you can afford to lose. Shares of DIMEZ were trading around 14 cents on Friday January 5.
ClearStory Systems, Inc. (OTC: CSYS) On May 3, 2006, ClearStory Systems, Inc. completed the disposition of assets pursuant to an agreement dated as of March 10, 2006 by and between ClearStory Systems, Inc. and Datawatch Corporation. Under the terms of the agreement, ClearStory Systems sold substantially all of the assets of its business unit that engaged in document solutions business activities, which are primarily fixed content, report management and electronic statement presentment, to Datawatch. At the closing on May 3, 2006, the Company received approximately $4.3 million in cash from Datawatch. In addition, Datawatch will pay the ClearStory Systems 30% of the future net revenues from all of the ClearStory Systems' former business unit's related products and services sold for the 18 months following the closing date. The closing of this transaction will allow ClearStory Systems to focus on its core digital media businesses. Henry F. Nelson, ClearStory chief executive officer, stated, "Over the past two years, we have made significant investments in our digital media platform, and this transaction allows us to concentrate our development and marketing energy on leveraging that investment, which has also been the recommendation of several industry analysts." On November 16, 2006 the company announced EContent Magazine has selected ClearStory Systems for the 2006 EContent 100 List of Companies that Matter Most in the Digital Content Industry. ClearStory's inclusion in the list demonstrates how important digital media-video, digital images, graphics, presentations, flash animation, and publishing files-has become for marketing, corporate and overall communications today. ClearStory's ActiveMedia suite of solutions manages the digital media supply chain-from creation to consumption-helping companies to repurpose, exploit and monetize this high value content for competitive advantage, new revenue streams, and marketing agility. "We nominate companies that continue to innovate and deliver products and services that further the evolution of the digital content industry," stated Michelle Manafy, editor-in-chief of EContent Magazine. Over the past year, EContent has reported on ClearStory's advanced DAM capabilities that power an innovative new business model for leading advertising agency, TracyLocke, and the digital media enterprise initiatives at Sony Pictures Entertainment. "To win a spot on this prestigious list is a real honor and greatly rewarding for our dedicated team. We are pleased that EContent has recognized our successful progress and the market adoption of ClearStory's award winning suite of digital media solutions," said Henry F. Nelson, ClearStory president and CEO. The EContent100 list is available in the December 2006 print issue of EContent and online at www.econtentmag.com. Shares of CSYS are thinly traded. The stock was trading around 12 cents on Friday January 5. The last available SEC filing shows the number of outstanding shares of CSYS to be about 6 million.
Well, all right, that's it for now… place your bets, sit back and relax. Remember, this is speculation not investing and quite often we get rewarded BIG for taking a chance…
Stockprowler.com does not receive compensation from companies we profile or from third parties... we never have and never will. We use our own money when we buy stocks, and even though we usually take a position in a stock before we profile a company, our purchases are small relative to the public float so that the effect on the stock price when we buy or sell is minimal. Please read our full disclaimer.
Also,
contrary to a commonly held belief, Stockprowler does not have access
to insider information, nor do we want to because trading on insider
information is illegal! All information contained in our reports is
available in the public record... and any written or verbal communication
with company CEOs/IR people strictly adheres to this rule.
Good Trading... Stockprowler
|
|
|
|
Copyright © 2007 Intervast Corp. All rights reserved. | Advertise | Disclaimer | Mailbag |